After years of reform and opening, China has become the world’s second-largest pharmaceutical market. The pharmaceutical manufacturing has been developed not only overseas but also in China, and therefore international as well as Chinese regulatory guidelines for manufacturing are equally important. This is where ACCESTRA builds a bridge, converging various GMP requirements with respect of culture, language and knowledge differences. We provide compliance service for overseas companies with their production China as well as Chinese companies with overseas production. According to your needs, we can also conduct third-party audits, provide gap analysis and improvement programs.
Please contact us for more information about the following service:
- Overseas On-site Audit and Mock Inspection Prior to NMPA’s Inspection
- Meeting the Requirements of Overseas On-site Inspection Conducted by NMPA
- Guidance on Correction of GMP Deficiencies